Results from phase 2 registration trial of SL-401 in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): Lead-in completed, expansion stage ongoing.

被引：4

作者：

Pemmaraju, Naveen

Lane, Andrew A.

Sweet, Kendra Lynn

Stein, Anthony Selwyn

Vasu, Sumithira

Blum, William G.

Rizzieri, David

Wang, Eunice S.

Duvic, Madeleine

Chen, Janice

Shemesh, Shay

McDonald, Peter

Brooks, Christopher

Kantarjian, Hagop M.

Konopleva, Marina

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[2] Dana Farber Canc Inst, Jamaica, NY USA

[3] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[4] City Hope Natl Med Ctr, Duarte, CA 91010 USA

[5] Ohio State Univ, Wexner Med Ctr, Columbus, OH 43210 USA

[6] Duke Univ, Med Ctr, Durham, NC USA

[7] Roswell Pk Canc Inst, Buffalo, NY 14263 USA

[8] Stemline Therapeut, New York, NY USA

来源：

关键词：

D O I：

10.1200/JCO.2016.34.15_suppl.7006

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

7006

引用

页数：4